ReviewOpen life sciences2025
Stem cell-based approaches for glaucoma treatment: a mini review.
Review in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glaucoma, a leading cause of irreversible blindness worldwide, is a progressive optic neuropathy characterized by the apoptotic loss of retinal ganglion cells (RGCs) and elevated intraocular pressure. Current intraocular pressure-lowering therapies often fail to halt disease progression, creating an urgent need for neuroprotective and regenerative strategies. Stem cell therapy, leveraging the dual capabilities of differentiation and paracrine signaling, has emerged as a transformative approach for glaucomatous optic neuropathy. This review critically appraises recent advancements in stem cell-based interventions, focusing on three core therapeutic strategies: RGC regeneration, paracrine-mediated neuroprotection, and restoration of trabecular meshwork function for intraocular pressure regulation. We systematically synthesized evidence from preclinical and clinical studies, highlighting the efficacy of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and adult stem cells in promoting retinal repair and neuroprotection. Despite promising results, significant translational challenges persist, including poor graft integration, tumorigenic risks, immune rejection, and the limitations of current animal models. We further discuss emerging technologies such as CRISPR/Cas9 gene editing and 3D bioprinting, which offer potential solutions for personalized and combinatory therapies. This review underscores that while stem cell therapy holds immense potential, overcoming these scientific and technical barriers is essential for its clinical translation into effective treatments for glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.